PD-1 inhibitors cause ILD in NSCLC patients with hypertension

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2022年 / 1925卷 / 1期
关键词：
D O I：
10.1007/s40278-022-23788-4
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：11 / 11
相关论文
共 50 条
  • [21] An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
    Jorgensen, Jan Trost
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2021, 21 (05) : 445 - 454
  • [22] Rheumatologic symptoms in oncologic patients on PD-1 inhibitors
    Kuswanto, Wilson F.
    MacFarlane, Lindsey A.
    Gedmintas, Lydia
    Mulloy, Alexandra
    Choueiri, Toni K.
    Bermas, Bonnie L.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2018, 47 (06) : 907 - 910
  • [23] Dynamic clonality of T cell receptor differentiate atypical progression in NSCLC patients treated with PD-1/PD-L1 inhibitors
    Han, Jiefei
    Wang, Zhijie
    Wang, Yuqi
    Chen, Si
    Bai, Hua
    Duan, Jianchun
    Wang, Jie
    CANCER RESEARCH, 2019, 79 (13)
  • [24] Serum CRP Decrease Has Predictive Value for LongTerm Disease Control by PD-1/ PD-L1 Inhibitors in Patients with NSCLC
    Matsuzawa, R.
    Morise, M.
    Tanaka, I.
    Koyama, J.
    Kimura, T.
    Kondoh, Y.
    Hase, T.
    Sakamoto, K.
    Hashimoto, N.
    Hasegawa, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S716 - S716
  • [25] Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC
    Bouhamama, Amine
    Leporq, Benjamin
    Faraz, Khuram
    Foy, Jean-Philippe
    Boussageon, Maxime
    Perol, Maurice
    Ortiz-Cuaran, Sandra
    Ghiringhelli, Francois
    Saintigny, Pierre
    Beuf, Olivier
    Pilleul, Frank
    FRONTIERS IN RADIOLOGY, 2023, 3
  • [26] Spectrum of Early Progression in Advanced NSCLC Patients Treated with PD-1 Inhibitors: Identifying Markers for Poor Outcome
    Nishino, M.
    Adeni, A.
    Lydon, C.
    Hatabu, H.
    Janne, P.
    Hodi, F. S.
    Awad, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1914 - S1915
  • [27] PD-1/PD-L1 inhibitors
    Sunshine, Joel
    Taube, Janis M.
    CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
  • [28] Impact of cachexia in advanced NSCLC patients treated with PD-1 inhibitor
    Jo, Hitomi
    Horinouchi, Hidehito
    Yagishita, Shigehiro
    Shinno, Yuki
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Yamamoto, Noboru
    Ohe, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [29] EVIDENCE-BASED VALUE OF PD-1 / PD-L1 INHIBITORS IN NSCLC: COMPARISON OF VALUE TO PRICE
    Doyle, J. J.
    Wood, B.
    VALUE IN HEALTH, 2018, 21 : S91 - S91
  • [30] PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
    Zhang, Ke
    Kong, Xiangyi
    Li, Yuan
    Wang, Zhongzhao
    Zhang, Lin
    Xuan, Lixue
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345